Education
About Us
Working with TipRanks
Follow Us
OmniAb (OABI)
NASDAQ:OABI
OABI Stock Chart & Stats
$1.61
-$0.06(-1.65%)
At close: 4:00 PM EST
$1.61
-$0.06(-1.65%)
Day’s Range― - ―
52-Week Range$1.22 - $4.21
Previous CloseN/A
Volume80.31K
Average Volume (3M)561.73K
Market Cap
$213.05M
Enterprise Value$164.87M
Total Cash (Recent Filing)$59.50M
Total Debt (Recent Filing)$21.07M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Mar 25, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding143,955,400
10 Day Avg. Volume481,153
30 Day Avg. Volume561,725
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)1.26
Price to Sales (P/S)13.73
P/FCF Ratio-8.72
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue7.82
Enterprise Value/Gross Profit10.21
Enterprise Value/Ebitda-3.46
Forecast
1Y Price Target
$6.00Price Target Upside272.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StrengthOmniAb bolstered its balance sheet by raising $30 million from the sale of 21.2 million shares and has approximately $59.5 million in cash on hand.
New Product LaunchThe company introduced a new product, OmniUltra, targeting CAR-T, radiopharma, and peptide-based biotech developers.
Partnership ExpansionOmniAb has increased its number of active partners to 104, up from 91 at the start of the year, with 32 in clinical development or already commercialized.
Bears Say
Earnings Per ShareOmniAb announced 2Q25 financial results, posting EPS of ($0.15) compared to our estimate of ($0.14) and consensus of ($0.15).
Revenue DeclineOmniAb reported a decline in revenues for 3Q25 due to lower milestone fees and service revenues.
Revenue GuidanceThe company's updated and lowered revenue guidance for FY2025 is down to $18-$22 million vs prior $20-$25 million.
OmniAb News
OABI FAQ
What was OmniAb’s price range in the past 12 months?
OmniAb lowest stock price was $1.22 and its highest was $4.21 in the past 12 months.
What is OmniAb’s market cap?
OmniAb’s market cap is $213.05M.
When is OmniAb’s upcoming earnings report date?
OmniAb’s upcoming earnings report date is Mar 25, 2026 which is in 126 days.
How were OmniAb’s earnings last quarter?
OmniAb released its earnings results on Nov 04, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.138 by -$0.002.
Is OmniAb overvalued?
According to Wall Street analysts OmniAb’s price is currently Undervalued.
Does OmniAb pay dividends?
OmniAb does not currently pay dividends.
What is OmniAb’s EPS estimate?
OmniAb’s EPS estimate is -0.09.
How many shares outstanding does OmniAb have?
OmniAb has 143,955,400 shares outstanding.
What happened to OmniAb’s price movement after its last earnings report?
OmniAb reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.138. Following the earnings report the stock price went down -4.054%.
Which hedge fund is a major shareholder of OmniAb?
Currently, no hedge funds are holding shares in OABI
OmniAb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (272.67% Upside)
$6.00 (272.67% Upside)
Hedge Fund Trend
Decreased
By 867.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $107.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 33.7%
Last 30 Days ▲ 33.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.21%
12-Months-Change
Fundamentals
Return on Equity
-22.37%
Trailing 12-Months
Asset Growth
-12.33%
Trailing 12-Months
Company Description
OmniAb
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
OABI Company Deck
OABI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
OmniAb's earnings call highlighted substantial progress in expanding partnerships and launching innovative technologies, notably OmniUltra and the xPloration program. However, financial challenges were evident with a decline in Q3 revenue and delayed milestones. Despite these setbacks, the company's strengthened financial position and strategic initiatives are promising.View all OABI earnings summariesOABI Stock 12 Month Forecast
Average Price Target
$6.00
▲(272.67% Upside)
Technical Analysis
Cartesian Therapeutics
―
Tiziana Life Sciences
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
5.69% Insiders
10.54% Mutual Funds
23.37% Other Institutional Investors
53.44% Public Companies and Individual Investors